PMV Pharmaceuticals (PMVP) is trading down at $1.78 (-0.56%), as of the latest quote. It operates in the Health Care sector.
| FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$18.9M | −$26.6M | −$34.9M | −$58.3M | −$77.0M | −$80.1M | −$85.4M | −$86.2M |
| Net income | −$17.5M | −$25.4M | −$34.4M | −$57.8M | −$73.3M | −$69.0M | −$58.7M | −$77.7M |
| EPS (diluted) | −$5.82 | −$8.35 | −$2.40 | −$1.28 | −$1.61 | −$1.44 | −$1.14 | −$1.48 |
| Balance sheet | ||||||||
| Cash and equivalents | — | $73.3M | $361.4M | $172.5M | $108.3M | $37.7M | $40.9M | $38.0M |
| Total assets | — | $103.0M | $365.5M | $331.6M | $270.3M | $252.2M | $191.3M | $116.6M |
| Total liabilities | — | $4.57M | $6.41M | $23.0M | $24.3M | $26.5M | $15.2M | $11.8M |
| Shareholders' equity | −$46.1M | −$70.5M | $359.1M | $308.6M | $246.0M | $225.7M | $176.1M | $104.7M |
| Cash flow | ||||||||
| Operating cash flow | −$15.2M | −$22.1M | −$32.7M | −$46.6M | −$63.8M | −$55.7M | −$51.3M | −$73.6M |
| Capital expenditure | $452.0K | $109.0K | $148.0K | $1.35M | $7.98M | $962.0K | $655.0K | $29.0K |
| Free cash flow | −$15.6M | −$22.2M | −$32.9M | −$47.9M | −$71.7M | −$56.6M | −$51.9M | −$73.6M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$21.9M | −$25.2M | −$21.6M | −$22.9M | −$22.5M | −$19.2M | −$19.0M | −$18.9M |
| Net income | −$19.2M | −$23.0M | −$17.4M | −$21.2M | −$21.1M | −$18.0M | −$18.0M | −$18.1M |
| EPS (diluted) | −$0.37 | −$0.45 | −$0.34 | −$0.41 | −$0.40 | −$0.33 | −$0.34 | −$0.34 |
| Balance sheet | ||||||||
| Cash and equivalents | $48.8M | $40.9M | $51.3M | $44.1M | $36.3M | $38.0M | $39.1M | $12.5M |
| Total assets | $223.5M | $191.3M | $170.6M | $152.9M | $133.8M | $116.6M | $96.6M | $82.1M |
| Total liabilities | $25.6M | $15.2M | $10.5M | $12.3M | $12.8M | $11.8M | $8.60M | $10.6M |
| Shareholders' equity | $197.9M | $176.1M | $160.1M | $140.6M | $121.0M | $104.7M | $88.0M | $71.5M |
| Cash flow | ||||||||
| Operating cash flow | −$16.8M | −$16.7M | −$18.3M | −$18.3M | −$19.8M | −$17.2M | −$19.7M | −$14.6M |
| Capital expenditure | $1.00K | $56.0K | $4.00K | $11.0K | −$1.00K | $15.0K | $0 | $0 |
| Free cash flow | −$16.8M | −$16.7M | −$18.3M | −$18.3M | −$19.8M | −$17.2M | −$19.7M | −$14.6M |
From PMV Pharmaceuticals's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning PMV Pharmaceuticals in our feed yet.